Dechert Advises Harvard Drug in US$1.12 Billion Sale to Cardinal Health

Cardinal Health today announced plans to acquire The Harvard Drug Group (THDG), a distributor of generic pharmaceuticals, over-the-counter medications and related products to retail, institutional and alternate care customers. THDG is currently owned by Court Square Capital Partners. Cardinal Health will pay US$1.12 billion using existing cash and new debt. The transaction is expected to close in the beginning of fiscal year 2016 subject to regulatory approvals and other customary closing conditions. Advising Harvard Drug were Dechert partner Craig Godshall, who led a team that included partners Richard Wild, Susan Hendrickson and James Fishkin; counsel John Ix; special counsel Francois Quintard-Morenas; and associates Bernardo Piereck, Sue Nieto, Jacob Greenberg, Leen Al-Alami, Steven Lorch, Eric Rubin, Violetta Kokolus, Thomas Cockriel, Shannon Rushing and Craig Falls.

About Dechert

Dechert is a global specialist law firm with a deep bench of experts focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.